Satoshi Morita
Kyoto University
836 Papers
4K Citations
Satoshi Morita is an academic researcher from Kyoto University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 66, co-authored 751 publications. Previous affiliations of Satoshi Morita include RMIT University & Yokohama City University Medical Center.
Chat about Author
Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka +20 more
TL;DR: In this article, an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan was conducted.
4.1K
Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi,Masaki Mandai,Takafumi Ikeda,Manabu Minami,Atsushi Kawaguchi,Toshinori Murayama,Masashi Kanai,Yukiko Mori,Shigemi Matsumoto,Shunsuke Chikuma,Noriomi Matsumura,Kaoru Abiko,Tsukasa Baba,Ken Yamaguchi,Akihiko Ueda,Yuko Hosoe,Satoshi Morita,Masayuki Yokode,Akira Shimizu,Tasuku Honjo,Ikuo Konishi +20 more
TL;DR: The encouraging safety and clinical efficacy of nivolumab in patients with platinum-resistant ovarian cancer indicate the merit of additional large-scale investigations (UMIN Clinical Trials Registry UMIN000005714).
1.1K
Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model
Tetsuhiro Kikuchi,Asuka Morizane,Daisuke Doi,Hiroaki Magotani,Hirotaka Onoe,Takuya Hayashi,Hiroshi Mizuma,Sayuki Takara,Ryosuke Takahashi,Haruhisa Inoue,Satoshi Morita,Michio Yamamoto,Keisuke Okita,Masato Nakagawa,Malin Parmar,Jun Takahashi +15 more
TL;DR: This preclinical study using a primate model indicates that human iPS cell-derived dopaminergic progenitors are clinically applicable for the treatment of patients with PD.
634
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito,Tatsuro Fukuhara,Naoki Furuya,Kana Watanabe,Shunichi Sugawara,Shunichiro Iwasawa,Yoshio Tsunezuka,Ou Yamaguchi,Morihito Okada,Kozo Yoshimori,Ichiro Nakachi,Akihiko Gemma,Koichi Azuma,Futoshi Kurimoto,Yukari Tsubata,Yuka Fujita,Hiromi Nagashima,Gyo Asai,Satoshi Watanabe,Masaki Miyazaki,Koichi Hagiwara,Toshihiro Nukiwa,Satoshi Morita,Kunihiko Kobayashi,Makoto Maemondo +24 more
TL;DR: A phase 3 trial to validate the results of the JO25567 study and report here the results from the preplanned interim analysis of the NEJ026 trial, which established the activity and manageable toxicity of erlotinib plus bevacizumab in patients with NSCLC.
577